Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Chief Executive Officer, Madan Jagasia, M.D., will present at ...

By contrast, the most common Cobenfy side effects in clinical trials were somewhat mild by comparison: nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, increased ...

Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of some unusual options trading on Thursday. Investors purchased 296,826 call options on the stock. This represents an increase of 866% ...

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

The stock's fall snapped a two-day winning streak.

Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

Dr. Robert A. Winn discusses efforts to increase diversity in clinical trials on an episode of Radio Health Journal.